Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030
Market Overview
During the forecast period, the Biodefense Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.01%.
In preparation for potential bioterrorism attacks, governments are allocating substantial resources to vaccine research and development. Pharmaceutical companies that operate in the biodefense market have been presented with substantial opportunities to expand as a result of government initiatives to prepare for any form of bioterrorism. Additionally, governments worldwide are implementing initiatives to improve their biodefense capabilities. The biodefense market is experiencing growth because of increased funding for research and development, preparedness planning, infrastructure development, and the procurement of vaccines and medications.
Market segment insights
Anthrax, smallpox, botulism, influenza, radiation/nuclear, and other diseases comprise the Biodefense Market segmentation organized by disease type.
The segmentation of the Biodefense Market is based on the treatment, which includes vaccination and medication.
Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Biodefense market held the greatest market share. This is a result of the increasing prevalence of infectious diseases in the region, including HIV, viral hepatitis, and influenza. For example, the Centers for Disease Control and Prevention (CDC) estimated that approximately 9 million individuals in the United States were diagnosed with the influenza virus in 2021. This trend is anticipated to continue as antimicrobial resistance continues to increase. Furthermore, the market is anticipated to be driven by the increasing demand for affordable diagnostic tests, vaccines, and therapeutics to combat these infectious diseases.
The second-largest market share in the Europe Biodefense market is attributed to the increasing prevalence of chronic diseases and the increase in research and development activities for biodefense solutions throughout the region. Additionally, the German biodefense market was identified as having the greatest market share, while the Rest of Europe biodefense market is anticipated to be the fastest-growing market in the European region.
It is anticipated that the Asia-Pacific Biodefense market will experience substantial growth from 2023 to 2030. The primary factor fueling the market's growth is the rise in the prevalence of the patient population throughout the region. The region's consumers are facing a significant health risk due to the widespread epidemics of infectious diseases, including influenza and Covid-19, as well as the rise in the number of reported infections of communicable diseases. Moreover, the Japan Biodefense market is anticipated to have the highest market share, while the Rest of Asia-Pacific Biodefense market is anticipated to be the fastest-growing market in the Asia-Pacific region.
The Middle East, Africa, and Latin America comprise the Rest of the World. An increase in the prevalence of infectious diseases, including influenza and Covid-19, is expected to drive growth in the biodefense market in the regions.
Major Players
Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are among the key companies in the Biodefense Market.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 BIODEFENSE BUDGET, BY REGION, 2023 (USD MILLION)
TABLE 3 GLOBAL BIODEFENSE MARKET, 2019–2030 (USD MILLION)
TABLE 4 GLOBAL BIODEFENSE MARKET, BY REGION, 2019-2030 (USD MILLION)
TABLE 5 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 6 NORTH AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE 2019-2030 (USD MILLION)
TABLE 9 US: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 10 US: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 11 US: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE,2019-2030 (USD MILLION)
TABLE 12 CANADA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 13 CANADA: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 14 CANADA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 15 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 16 EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 17 EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 18 EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 19 GERMANY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 20 GERMANY: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 21 GERMANY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 22 UK: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 23 UK: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 24 UK: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 25 FRANCE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 26 FRANCE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 27 FRANCE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 28 ITALY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 29 ITALY: BIODEFENSE MARKET, BY TREATMENT, 2019–2030 (USD MILLION)
TABLE 30 ITALY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 31 SPAIN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 32 SPAIN: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 33 SPAIN: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 34 REST OF EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 35 REST OF EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 36 REST OF EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 41 JAPAN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 42 JAPAN: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 43 JAPAN: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 44 INDIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 45 INDIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 46 INDIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 47 SOUTH KOREA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 48 SOUTH KOREA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 49 SOUTH KOREA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 50 AUSTRALIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 51 AUSTRALIA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 52 AUSTRALIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 53 REST OF ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 54 REST OF ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 55 REST OF ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 56 REST OF THE WORLD: BIODEFENSE MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 57 REST OF THE WORLD: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 58 REST OF THE WORLD: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 59 REST OF THE WORLD: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 60 MIDDLE EAST: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 61 MIDDLE EAST: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 62 MIDDLE EAST: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 63 AFRICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 64 AFRICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 65 AFRICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 66 LATIN AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2030 (USD MILLION)
TABLE 67 LATIN AMERICA: BIODEFENSE MARKET BY TREATMENT, 2019-2030 (USD MILLION)
TABLE 68 LATIN AMERICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2030 (USD MILLION)
TABLE 69 MAJOR PLAYERS IN GLOBAL BIODEFENSE MARKET
TABLE 1 MOST ACTIVE PLAYER IN GLOBAL BIODEFENSE MARKET
TABLE 2 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 3 PARTNERSHIP/ COLLABORATION /AGREEMENT
TABLE 4 ACQUISITION/EXPANSION/INVESTMENT
TABLE 5 EMERGENT: PRODUCTS OFFERED
TABLE 6 EMERGENT: KEY DEVELOPMENTS
TABLE 7 BAVARIAN NORDIC: PRODUCTS OFFERED
TABLE 8 BAVARIAN NORDIC: KEY DEVELOPMENTS
TABLE 9 ALTIMMUNE: PRODUCTS OFFERED
TABLE 10 DYNAVAX TECHNOLOGIES: PRODUCTS OFFERED
TABLE 11 DYNAVAX TECHNOLOGIES: KEY DEVELOPMENTS
TABLE 12 SIGA TECHNOLOGIES: PRODUCTS OFFERED
TABLE 13 SIGA TECHNOLOGIES: KEY DEVELOPMENTS
TABLE 14 ELUSYS THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 15 ELUSYS THERAPEUTICS, INC.: KEY DEVELOPMENTS
TABLE 16 FABENTECH BIOTECH: PRODUCTS OFFERED
TABLE 17 FABENTECH BIOTECH: KEY DEVELOPMENTS
TABLE 18 CLEVELAND BIOLABS, INC.: PRODUCTS OFFERED
TABLE 19 OLOGY BIOSERVICES, INC.: PRODUCTS OFFERED
TABLE 20 OLOGY BIOSERVICES, INC.: KEY DEVELOPMENTS
TABLE 21 NOVAVAX, INC.: PRODUCTS OFFERED
TABLE 22 NOVAVAX, INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL BIODEFENSE MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: GLOBAL BIODEFENSE MARKET
FIGURE 4 DRIVER IMPACT ANALYSIS
FIGURE 5 RESTRAINT IMPACT ANALYSIS
FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL BIODEFENSE MARKET
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIODEFENSE MARKET
FIGURE 8 GLOBAL BIODEFENSE MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 9 GLOBAL BIODEFENSE MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10 GLOBAL BIODEFENSE MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 11 GLOBAL BIODEFENSE MARKET, BY REGION, 2023 & 2030 (USD MILLION)
FIGURE 12 NORTH AMERICA MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
FIGURE 13 NORTH AMERICA: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
FIGURE 14 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
FIGURE 15 EUROPE MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)
FIGURE 16 EUROPE: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
FIGURE 17 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2030 (USD MILLION)
FIGURE 18 ASIA-PACIFIC MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
FIGURE 19 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019 & 2030 (USD MILLION)
FIGURE 20 ASIA-PACIFIC: BIODEFENSE MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 21 REST OF THE WORLD MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2030 (USD MILLION)
FIGURE 22 REST OT THE WORLD: BIODEFENSE MARKET, BY REGION, 2019 & 2030 (USD MILLION)
FIGURE 23 REST OF THE WORLD: BIODEFENSE MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 25 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL BIODEFENSE MARKET
FIGURE 26 GLOBAL BIODEFENSE MARKET: COMPETITIVE LANDSCAPE
FIGURE 27 MAJOR PLAYERS SALES, 2023
FIGURE 28 MAJOR PLAYERS R&D EXPENDITURE, 2023
FIGURE 29 EMERGENT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 EMERGENT: SWOT ANALYSIS
FIGURE 31 BAVARIAN NORDIC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 BAVARIAN NORDIC: SWOT ANALYSIS
FIGURE 33 ALTIMMUNE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 DYNAVAX TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 SIGA TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 SIGA TECHNOLOGIES: SWOT ANALYSIS
FIGURE 37 FABENTECH BIOTECH: SWOT ANALYSIS
FIGURE 38 CLEVELAND BIOLABS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 NOVAVAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 NOVAVAX, INC.: SWOT ANALYSIS
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們